Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).
Date Range: 

 CytRxTRACON PharmaceuticalsBrainstorm Cell TherapeuticsLa Jolla PharmaceuticalDyadic International
SymbolOTCMKTS:CYTRNASDAQ:TCONNASDAQ:BCLINASDAQ:LJPCNASDAQ:DYAI
Price Information
Current Price$2.12$7.34$3.28$4.13$4.82
52 Week RangeN/ABuyBuyBuyBuy
MarketRank™
Overall Score0.61.71.31.71.3
Analysis Score0.03.53.53.53.5
Community Score2.82.83.02.62.3
Dividend Score0.00.00.00.00.0
Ownership Score0.01.70.01.70.0
Earnings & Valuation Score0.00.60.00.60.6
Analyst Ratings
Consensus RecommendationN/ABuyBuyBuyBuy
Consensus Price TargetN/A$16.67$12.00$11.50$11.00
% Upside from Price TargetN/A127.07% upside265.85% upside178.45% upside128.22% upside
Trade Information
Market Cap$77.34 million$113.62 million$117.17 million$113.28 million$132.81 million
Beta2.122.020.372.840.14
Average Volume142,003439,6991,066,012861,052531,231
Sales & Book Value
Annual Revenue$250,000.00$3 millionN/A$23.05 million$1.68 million
Price / Sales309.3537.87N/A4.9179.05
CashflowN/AN/AN/AN/AN/A
Price / CashN/AN/AN/AN/AN/A
Book Value$0.45 per share$0.67 per share($0.54) per share($2.21) per share$1.32 per share
Price / Book4.7110.96N/A-1.873.65
Profitability
Net Income$-7,160,000.00$-22,670,000.00$-23,250,000.00$-116,510,000.00$-8,310,000.00
EPSN/A($7.47)($1.06)($4.30)($0.31)
Trailing P/E Ratio0.00N/AN/AN/AN/A
Forward P/E RatioN/AN/AN/AN/A
P/E GrowthN/AN/AN/AN/AN/A
Net MarginsN/AN/AN/A-205.85%-539.34%
Return on Equity (ROE)-62.90%-273.66%-339.86%N/A-27.54%
Return on Assets (ROA)-50.65%-84.56%-144.74%-55.80%-26.33%
Dividend
Annual PayoutN/AN/AN/AN/AN/A
Dividend YieldN/AN/AN/AN/AN/A
Three-Year Dividend GrowthN/AN/AN/AN/AN/A
Payout RatioN/AN/AN/AN/AN/A
Years of Consecutive Dividend GrowthN/AN/AN/AN/AN/A
Debt
Debt-to-Equity RatioN/A0.13%N/AN/AN/A
Current Ratio3.13%2.76%4.72%2.25%18.13%
Quick Ratio3.13%2.76%4.72%1.86%18.13%
Ownership Information
Institutional Ownership Percentage0.04%42.03%21.58%74.38%20.15%
Insider Ownership Percentage22.00%23.30%22.10%33.39%23.90%
Miscellaneous
Employees41840596
Shares Outstanding36.48 million15.48 million35.72 million27.43 million27.55 million
Next Earnings Date5/13/2021 (Estimated)5/12/2021 (Estimated)4/26/2021 (Confirmed)5/3/2021 (Estimated)5/13/2021 (Estimated)
OptionableOptionableNot OptionableOptionableOptionableNot Optionable
SourceHeadline
Advancing Dyadics proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trialAdvancing Dyadic's proprietary COVID-19 vaccine candidate, DYAI-100, towards a first-in-human Phase 1 clinical trial
finchannel.com - April 21 at 3:10 PM
Dyadic International, Inc. (NASDAQ:DYAI) Short Interest UpdateDyadic International, Inc. (NASDAQ:DYAI) Short Interest Update
americanbankingnews.com - April 17 at 2:08 AM
Were Not Very Worried About Dyadic Internationals (NASDAQ:DYAI) Cash Burn RateWe're Not Very Worried About Dyadic International's (NASDAQ:DYAI) Cash Burn Rate
nasdaq.com - April 14 at 6:27 PM
Analyzing Voyager Therapeutics (NASDAQ:VYGR) & Dyadic International (NASDAQ:DYAI)Analyzing Voyager Therapeutics (NASDAQ:VYGR) & Dyadic International (NASDAQ:DYAI)
americanbankingnews.com - April 14 at 6:40 AM
What Kind Of Shareholders Hold The Majority In Dyadic International, Inc.s (NASDAQ:DYAI) Shares?What Kind Of Shareholders Hold The Majority In Dyadic International, Inc.'s (NASDAQ:DYAI) Shares?
finance.yahoo.com - April 11 at 1:47 PM
DYAI: Headed to the ClinicDYAI: Headed to the Clinic
finance.yahoo.com - April 8 at 12:13 PM
Reviewing Cellectis (NASDAQ:CLLS) and Dyadic International (NASDAQ:DYAI)Reviewing Cellectis (NASDAQ:CLLS) and Dyadic International (NASDAQ:DYAI)
americanbankingnews.com - April 1 at 6:10 AM
UPDATE — Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical TrialUPDATE — Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
morningstar.com - March 31 at 3:07 PM
Dyadic International (NASDAQ:DYAI) Issues  Earnings Results, Beats Estimates By $0.01 EPSDyadic International (NASDAQ:DYAI) Issues Earnings Results, Beats Estimates By $0.01 EPS
americanbankingnews.com - March 31 at 7:48 AM
Dyadic Reports 2020 Year End Results and Recent Company ProgressDyadic Reports 2020 Year End Results and Recent Company Progress
finance.yahoo.com - March 30 at 6:59 PM
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical TrialUPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
markets.businessinsider.com - March 29 at 9:37 AM
UPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical TrialUPDATE -- Dyadic Advancing Proprietary Owned COVID-19 vaccine candidate, DYAI-100, Towards Human Clinical Trial
finance.yahoo.com - March 29 at 9:37 AM
Dyadic International, Inc.: Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic International, Inc.: Dyadic and Medytox To Develop Vaccines Against COVID-19 Variants
finanznachrichten.de - March 25 at 3:16 AM
Dyadic, Medytox To Co-develop Vaccines Against COVID-19 VariantsDyadic, Medytox To Co-develop Vaccines Against COVID-19 Variants
markets.businessinsider.com - March 22 at 11:45 PM
DYAI Stock Price Increases Over 30% Pre-Market: Why It HappenedDYAI Stock Price Increases Over 30% Pre-Market: Why It Happened
pulse2.com - March 22 at 1:44 PM
DYAI: Human Trials Around the CornerDYAI: Human Trials Around the Corner
finance.yahoo.com - March 22 at 1:44 PM
Why Dyadic Internationals Stock is Up During Todays SessionWhy Dyadic International's Stock is Up During Today's Session
msn.com - March 22 at 1:44 PM
Dyadic and Medytox To Develop Vaccines Against COVID-19 VariantsDyadic and Medytox To Develop Vaccines Against COVID-19 Variants
finance.yahoo.com - March 22 at 8:43 AM
Dyadics COVID-19 Vaccine Candidate Comes One Step Closer To Enter Human TrialsDyadic's COVID-19 Vaccine Candidate Comes One Step Closer To Enter Human Trials
benzinga.com - March 18 at 2:44 PM
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
finance.yahoo.com - March 18 at 8:50 AM
Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100Dyadic Advancing Towards Human Clinical Trial of its SARS-CoV-2-S-RBD vaccine candidate, DYAI-100
finance.yahoo.com - March 18 at 8:50 AM
Dyadic International, Inc.: Dyadic to Report Fourth Quarter and Full Year 2020 Financial ResultsDyadic International, Inc.: Dyadic to Report Fourth Quarter and Full Year 2020 Financial Results
finanznachrichten.de - March 16 at 7:01 PM
Dyadic to Report Fourth Quarter and  Full Year 2020 Financial ResultsDyadic to Report Fourth Quarter and Full Year 2020 Financial Results
finance.yahoo.com - March 16 at 7:01 PM
Dyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web MeetingDyadic Announces Scientific Achievements Reported During ZAPI Stakeholders Virtual Web Meeting
finance.yahoo.com - March 9 at 8:40 AM
Dyadic International, Inc.: Dyadic to Present at Upcoming EventsDyadic International, Inc.: Dyadic to Present at Upcoming Events
finanznachrichten.de - February 15 at 12:43 PM
DateCompanyBrokerageAction
7/16/2019CytRxHC WainwrightReiterated Rating
4/16/2021TRACON PharmaceuticalsBTIG ResearchUpgrade
4/1/2021TRACON PharmaceuticalsJonestradingInitiated Coverage
2/10/2021TRACON PharmaceuticalsMaxim GroupInitiated Coverage
3/1/2019TRACON PharmaceuticalsNeedham & Company LLCReiterated Rating
12/18/2018Brainstorm Cell TherapeuticsDawson JamesReiterated Rating
3/10/2021La Jolla PharmaceuticalChardan CapitalReiterated Rating
6/24/2020La Jolla PharmaceuticalCi CapitalReiterated Rating
11/25/2019La Jolla PharmaceuticalSunTrust BanksDowngrade
3/5/2019La Jolla PharmaceuticalCowenReiterated Rating
1/23/2019La Jolla PharmaceuticalJPMorgan Chase & Co.Upgrade
1/14/2019La Jolla PharmaceuticalJefferies Financial GroupUpgrade
8/14/2020Dyadic InternationalNoble FinancialReiterated Rating
(Data available from 4/22/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.